Affy to Expand into Flow Cytometry, Immunology Markets with Planned $330M eBioscience Acquisition | GenomeWeb

This story was originally posted on Dec. 1

By Justin Petrone

Affymetrix last week announced plans to acquire eBioscience, a privately held firm that sells flow cytometry and immunoassay reagents for immunology and oncology research and diagnostics.

The Santa Clara, Calif.-based array vendor said it will spend $330 million in cash and debt to buy eBioscience, with the transaction expected to close before the end of this year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.